- Home
- APH vs NVS Comparison
APH vs NVS Comparison
Compare APH & NVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | APH | NVS |
|---|---|---|
| Founded | 1932 | 1895 |
| Country | United States | Switzerland |
| Employees | N/A | 75267 |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 162.1B | 310.4B |
| IPO Year | 1994 | N/A |
Fundamental Metrics
Financial Performance| Metric | APH | NVS |
|---|---|---|
| Price | $136.44 | $161.60 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 11 | 4 |
| Target Price | ★ $154.73 | $118.00 |
| AVG Volume (30 Days) | ★ 8.2M | 2.5M |
| Earning Date | 04-29-2026 | 01-01-0001 |
| Dividend Yield | 0.76% | ★ 1.94% |
| EPS Growth | ★ 73.96 | N/A |
| EPS | ★ 3.34 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $37.20 | $2.56 |
| Revenue Next Year | $12.03 | $4.91 |
| P/E Ratio | $39.41 | ★ $23.13 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $56.45 | $97.72 |
| 52 Week High | $167.13 | $170.46 |
Technical Indicators
Market Signals| Indicator | APH | NVS |
|---|---|---|
| Relative Strength Index (RSI) | 45.66 | 52.48 |
| Support Level | $126.17 | $113.19 |
| Resistance Level | $143.92 | $170.46 |
| Average True Range (ATR) | 5.26 | 2.43 |
| MACD | -1.22 | -1.29 |
| Stochastic Oscillator | 36.60 | 35.92 |
Price Performance
Historical ComparisonAbout APH Amphenol Corporation
Amphenol is a global supplier of connectors, sensors, and interconnect systems. It holds the second-largest connector market share globally and sells into the automotive, broadband, commercial air, industrial, IT and data communications, military, mobile devices, and mobile networks end markets. Amphenol is diversified geographically, with operations in 40 countries.
About NVS Novartis AG
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.